The Trials Were Always There — Patients Just Couldn’t Find Them
This structural problem calls for a structural solution, requiring no new science, regulation, or data.
The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design
New FDA guidance on the use of Bayesian statistics signals a broader shift in accommodating more flexible clinical trial designs and the complexities of diseases such as certain cancers and rare disorders, which may lead to more efficient trials, lower development costs, and faster innovation.
presented by
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
presented by
The Role of RWD in Revolutionizing Clinical Trial Design
Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people.
When Patients Win, Everyone Wins
When was the last time you asked a patient to contribute to trial design? Have you ever asked a patient to contribute to a protocol? Patient-centricity benefits the entire healthcare ecosystem.
Tackling Global Obesity: The New, Holistic Frontier for Clinical Trials
To conduct meaningful research, we must be sure to view these studies through patients’ eyes. The patient perspective — in all its diversity — must be embedded into clinical trials from the very start.
The Opportunity for Digital Innovation in Oncology Drug Development
Solving three major challenges in the development of new oncology drugs
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
It’s Time to Give Patients a Seat at the Table
Game-changing advances can be achieved by integrating patient collaboration and priorities into the full span of trial design.
The Evolution of Patient-Centered Clinical Trial Design
Clinical trial design will be one of the topics discussed at the upcoming INVEST Digital Health conference in Dallas on October 26. THREAD Clinical Trial Design Director Noah Goodson highlighted some of the milestones the sector has seen in recent years.
Enhancing patient care in research through digital transformation
The paradigm shift to more patient-centric, technology-enabled decentralized clinical trials during the pandemic has created an opportunity to strengthen patient care in research.
Defining the new age of clinical development: How COVID-19 is rewriting the rules for testing and trials
I’m tired of hearing the phrase, “after-Covid.” We know that in the next few months the first major wave in North America will be over, but there is no going back to the way life was on March 15. Certainly not immediately, and maybe not ever. There’s no magic switch that will allow us to […]
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
The Covid-19 crisis is the right time to adopt decentralized clinical trials
Reducing trial timelines has to be a long-term industry imperative, and digital technology can help valuable research continue to move forward while keeping participants safe.
Precision medicine will have a transformative effect on clinical trials
Experimental models such as virtual clinical trials are designed with patient-generated data in mind.
Novartis re-imagines clinical studies for eye diseases with new app through Apple ResearchKit
One goal of FocalView is to create a more accurate way to track and measure disease progression and develop more sensitive clinical trial endpoints from the comfort of patients' homes., adding more flexibility to clinical trial design.
Stem cell treatment trial blinded three women. What went wrong?
The analysis said that the consent forms signed by the women did not mention a clinical trial.
N of 1 – Reflections on extracting knowledge from data
There is enormous untapped potential in the N-of-1 clinical trial.